The FDA has been considering the historical controls question for several years, and its decision could affect approval of several other drugs in late-stage trials seeking similar monotherapy indications.
Used with permission from "The Pink Sheet." Clinical Psychiatry News Digital Network and "The Pink Sheet" are published by Elsevier.